THE HUMAN IMMUNODEFICIENCY VIRUS-1-ASSOCIATED PROTEIN, TAT1-86, IMPAIRS DOPAMINE TRANSPORTERS AND INTERACTS WITH COCAINE TO REDUCE NERVE TERMINAL FUNCTION : A NO-NET-FLUX MICRODIALYSIS STUDY
Identifieur interne : 001C54 ( Main/Curation ); précédent : 001C53; suivant : 001C55THE HUMAN IMMUNODEFICIENCY VIRUS-1-ASSOCIATED PROTEIN, TAT1-86, IMPAIRS DOPAMINE TRANSPORTERS AND INTERACTS WITH COCAINE TO REDUCE NERVE TERMINAL FUNCTION : A NO-NET-FLUX MICRODIALYSIS STUDY
Auteurs : M. J. Ferris [États-Unis] ; D. Frederick-Duus [États-Unis] ; J. Fadel [États-Unis] ; C. F. Mactutus [États-Unis] ; R. M. Booze [États-Unis]Source :
- Neuroscience [ 0306-4522 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
-Injection drug use accounts for approximately one-third of human immunodeficiency virus (HIV) infections in the United States. HIV-associated proteins have been shown to interact with various drugs of abuse to incite concerted neurotoxicity. One common area for their interaction is the nerve terminal, including dopamine transporter (DAT) systems. However, results regarding DAT function and regulation in HIV-infection, regardless of drug use, are mixed. Thus, the present experiments were designed to explicitly control Tat and cocaine administration in an in vivo rat model in order to reconcile differences that exist in the literature to date. We examined Tat plus cocaine-induced alterations using no-net-flux microdialysis, which is sensitive to alterations in DAT function, in order to test the potential for DAT as an early mediator of HIV-induced oxidative stress and neurode-generation in vivo. Within 5 h of intra-accumbal administration of the HIV-associated protein, Tat, we noted a significant reduction in local DAT efficiency with little change in DA overflow/release dynamics. Further, at 48 h post-Tat administration, we demonstrated a concerted effect of the HIV-protein Tat with cocaine on both uptake and release function. Finally, we discuss the extent to which DAT dysfunction may be considered a predecessor to generalized nerve terminal dysfunction. Characterization of DAT dysfunction in vivo may provide an early pharmacotherapeutic target, which in turn may prevent or attenuate downstream mediators of neurotoxicity (i.e., reactive species) to dopamine systems occurring in neuro-AIDS.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000140
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000154
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000139
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000077
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001C56
Links to Exploration step
Pascal:09-0199428Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">THE HUMAN IMMUNODEFICIENCY VIRUS-1-ASSOCIATED PROTEIN, TAT<sub>1-86</sub>
, IMPAIRS DOPAMINE TRANSPORTERS AND INTERACTS WITH COCAINE TO REDUCE NERVE TERMINAL FUNCTION : A NO-NET-FLUX MICRODIALYSIS STUDY</title>
<author><name sortKey="Ferris, M J" sort="Ferris, M J" uniqKey="Ferris M" first="M. J." last="Ferris">M. J. Ferris</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Frederick Duus, D" sort="Frederick Duus, D" uniqKey="Frederick Duus D" first="D." last="Frederick-Duus">D. Frederick-Duus</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fadel, J" sort="Fadel, J" uniqKey="Fadel J" first="J." last="Fadel">J. Fadel</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mactutus, C F" sort="Mactutus, C F" uniqKey="Mactutus C" first="C. F." last="Mactutus">C. F. Mactutus</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Booze, R M" sort="Booze, R M" uniqKey="Booze R" first="R. M." last="Booze">R. M. Booze</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0199428</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0199428 INIST</idno>
<idno type="RBID">Pascal:09-0199428</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000140</idno>
<idno type="stanalyst">FRANCIS 09-0199428 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000154</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000139</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000077</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000077</idno>
<idno type="wicri:doubleKey">0306-4522:2009:Ferris M:the:human:immunodeficiency</idno>
<idno type="wicri:Area/Main/Merge">001C56</idno>
<idno type="wicri:Area/Main/Curation">001C54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">THE HUMAN IMMUNODEFICIENCY VIRUS-1-ASSOCIATED PROTEIN, TAT<sub>1-86</sub>
, IMPAIRS DOPAMINE TRANSPORTERS AND INTERACTS WITH COCAINE TO REDUCE NERVE TERMINAL FUNCTION : A NO-NET-FLUX MICRODIALYSIS STUDY</title>
<author><name sortKey="Ferris, M J" sort="Ferris, M J" uniqKey="Ferris M" first="M. J." last="Ferris">M. J. Ferris</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Frederick Duus, D" sort="Frederick Duus, D" uniqKey="Frederick Duus D" first="D." last="Frederick-Duus">D. Frederick-Duus</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fadel, J" sort="Fadel, J" uniqKey="Fadel J" first="J." last="Fadel">J. Fadel</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mactutus, C F" sort="Mactutus, C F" uniqKey="Mactutus C" first="C. F." last="Mactutus">C. F. Mactutus</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Booze, R M" sort="Booze, R M" uniqKey="Booze R" first="R. M." last="Booze">R. M. Booze</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychology, Program in Behavioral Neuroscience, University of South Carolina</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
<settlement type="city">Columbia (Caroline du Sud)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Sud</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine</s1>
<s2>Columbia, SC 29208</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carrier protein</term>
<term>Cocaine</term>
<term>Dopamine</term>
<term>Human immunodeficiency virus</term>
<term>Microdialysis</term>
<term>Nerve ending</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus immunodéficience humaine</term>
<term>Protéine transport</term>
<term>Dopamine</term>
<term>Cocaïne</term>
<term>Terminaison nerveuse</term>
<term>Microdialyse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">-Injection drug use accounts for approximately one-third of human immunodeficiency virus (HIV) infections in the United States. HIV-associated proteins have been shown to interact with various drugs of abuse to incite concerted neurotoxicity. One common area for their interaction is the nerve terminal, including dopamine transporter (DAT) systems. However, results regarding DAT function and regulation in HIV-infection, regardless of drug use, are mixed. Thus, the present experiments were designed to explicitly control Tat and cocaine administration in an in vivo rat model in order to reconcile differences that exist in the literature to date. We examined Tat plus cocaine-induced alterations using no-net-flux microdialysis, which is sensitive to alterations in DAT function, in order to test the potential for DAT as an early mediator of HIV-induced oxidative stress and neurode-generation in vivo. Within 5 h of intra-accumbal administration of the HIV-associated protein, Tat, we noted a significant reduction in local DAT efficiency with little change in DA overflow/release dynamics. Further, at 48 h post-Tat administration, we demonstrated a concerted effect of the HIV-protein Tat with cocaine on both uptake and release function. Finally, we discuss the extent to which DAT dysfunction may be considered a predecessor to generalized nerve terminal dysfunction. Characterization of DAT dysfunction in vivo may provide an early pharmacotherapeutic target, which in turn may prevent or attenuate downstream mediators of neurotoxicity (i.e., reactive species) to dopamine systems occurring in neuro-AIDS.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001C54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= Main |étape= Curation |type= RBID |clé= Pascal:09-0199428 |texte= THE HUMAN IMMUNODEFICIENCY VIRUS-1-ASSOCIATED PROTEIN, TAT1-86, IMPAIRS DOPAMINE TRANSPORTERS AND INTERACTS WITH COCAINE TO REDUCE NERVE TERMINAL FUNCTION : A NO-NET-FLUX MICRODIALYSIS STUDY }}
This area was generated with Dilib version V0.6.33. |